N M Berezhnaya

Summary

Affiliation: National Academy of Sciences of Ukraine
Country: Ukraine

Publications

  1. Berezhnaya N, Kovalchuk E, Vinnichuk Y, Spivak S, Belova O. Experimental immunotherapy of mice with transplanted MC-rhabdomyosarcoma resistant to doxorubicin. Eksp Onkol. 2004;26:63-6 pubmed
    ..Adoptive in vivo therapy of DOX-resistant Mh-RMS is effective if LAC or their combination with DOX at a low dose are administered. ..
  2. Bereznaya N, Kirnasovskaya E, Vinnichuk Y, Belova O, Lukyanova N. Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol. 2008;30:295-9 pubmed
    ..Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes. ..
  3. Berezhnaya N, Vinnichuk Y, Belova O. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin. Exp Oncol. 2008;30:52-5 pubmed
    ..There was no such effect in the case of sensitive tumors. To elevate antitumor activity of LAK toward MC-rhabdomyosarcoma and B16 melanoma cells, low doses of doxorubicin could be used at certain conditions of LAK generation. ..

Detail Information

Publications3

  1. Berezhnaya N, Kovalchuk E, Vinnichuk Y, Spivak S, Belova O. Experimental immunotherapy of mice with transplanted MC-rhabdomyosarcoma resistant to doxorubicin. Eksp Onkol. 2004;26:63-6 pubmed
    ..Adoptive in vivo therapy of DOX-resistant Mh-RMS is effective if LAC or their combination with DOX at a low dose are administered. ..
  2. Bereznaya N, Kirnasovskaya E, Vinnichuk Y, Belova O, Lukyanova N. Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol. 2008;30:295-9 pubmed
    ..Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes. ..
  3. Berezhnaya N, Vinnichuk Y, Belova O. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin. Exp Oncol. 2008;30:52-5 pubmed
    ..There was no such effect in the case of sensitive tumors. To elevate antitumor activity of LAK toward MC-rhabdomyosarcoma and B16 melanoma cells, low doses of doxorubicin could be used at certain conditions of LAK generation. ..